Hepion Pharmaceuticals CEO Resigns Amidst Financial Distress; Interim CEO and New Directors Appointed

summarizeSummary

Hepion Pharmaceuticals' CEO resigned immediately for personal reasons, prompting the appointment of an interim CEO and new directors, just days after the company reported going concern doubts and delisting.

check_boxKey Events

• CEO Resignation

  Dr. Kaouthar Lbiati resigned as Chief Executive Officer for personal reasons, effective immediately, on March 16, 2026.

• Interim CEO Appointed

  Gary Stetz was appointed as interim Chief Executive Officer and director.

• Board Restructuring

  Vincent LoPriore was appointed Executive Chairman, and Sireesh Appajosyula and Chase LoPriore were appointed as directors.

• Context of Financial Distress

  This leadership change follows a recent 10-K filing (March 12, 2026) which raised substantial doubt about the company's ability to continue as a going concern, noted its delisting from Nasdaq, and reported zero commercial product revenue.

auto_awesomeAnalysis

The immediate resignation of Dr. Kaouthar Lbiati as CEO for "personal reasons," just days after the company disclosed substantial doubt about its ability to continue as a going concern and its delisting from Nasdaq, signals significant instability at the top. This leadership overhaul, including the appointment of an interim CEO and multiple new directors, suggests the board is attempting to navigate the company's severe financial challenges and potentially explore new strategic directions. Investors should view this as a critical development given the company's precarious financial position and lack of commercial revenue.